209 related articles for article (PubMed ID: 34362570)
1. [Metastatic Crohn's disease of the umbilicus: An exceptional location].
Letzelter M; Andrianjafy C; Marin S; Rocour S; De Ybarlucea LR; Maillard H
Rev Med Interne; 2022 Jan; 43(1):54-56. PubMed ID: 34362570
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Crohn's disease of the umbilicus.
McLelland J; Griffin SM
Clin Exp Dermatol; 1996 Jul; 21(4):318-9. PubMed ID: 8959912
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Crohn's disease despite infliximab therapy.
Campos S; Coutinho I; Cardoso JC; Portela F
An Bras Dermatol; 2017; 92(5 Suppl 1):104-106. PubMed ID: 29267462
[TBL] [Abstract][Full Text] [Related]
4. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
[TBL] [Abstract][Full Text] [Related]
5. Fistulising skin metastases in Crohn's disease: a case report and review of the literature.
Elger T; Loibl J; Buechler C; Haferkamp S; Werner J; Drexler K; Hohenleutner U; Guelow K; Kunst C; Kandulski A; Goeggelmann P; Mueller M; Tews HC
J Med Case Rep; 2024 May; 18(1):252. PubMed ID: 38762485
[TBL] [Abstract][Full Text] [Related]
6. Response of cutaneous Crohn's disease to infliximab and methotrexate.
Konrad A; Seibold F
Dig Liver Dis; 2003 May; 35(5):351-6. PubMed ID: 12846408
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn's disease during infliximab therapy.
Numakura T; Tamada T; Nara M; Muramatsu S; Murakami K; Kikuchi T; Kobayashi M; Muroi M; Okazaki T; Takagi S; Eishi Y; Ichinose M
BMC Pulm Med; 2016 Feb; 16():30. PubMed ID: 26864464
[TBL] [Abstract][Full Text] [Related]
8. [Cutaneous metastatic Crohn's disease].
Ciubotaru V; Tattevin P; Cartron-Savin L; Le Gall F; Arvieux C; Gosselin M; Michelet C
Rev Med Interne; 2003 Mar; 24(3):198-201. PubMed ID: 12657443
[TBL] [Abstract][Full Text] [Related]
9. [Metastatic Crohn's disease].
Romero Gutiérrez M; Alcántara Torres M; Muñoz Rosas C; Gómez Moreno AZ; Guardiola Arévalo A; Rodríguez Merlo R; Carrobles Jiménez JM
Gastroenterol Hepatol; 2010; 33(6):440-4. PubMed ID: 20537428
[TBL] [Abstract][Full Text] [Related]
10. Anti-NMDAR encephalitis in Crohn's disease undergoing long-term infliximab treatment: A case report.
Oh SJ; Kwon YN; Lee CK; Lee JS
Front Immunol; 2022; 13():957575. PubMed ID: 36389693
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous manifestations of metastatic Crohn's disease.
Schneider SL; Foster K; Patel D; Shwayder T
Pediatr Dermatol; 2018 Sep; 35(5):566-574. PubMed ID: 29952016
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for the treatment of orofacial Crohn's disease.
Mahadevan U; Sandborn WJ
Inflamm Bowel Dis; 2001 Feb; 7(1):38-42. PubMed ID: 11233659
[TBL] [Abstract][Full Text] [Related]
14. [Cutaneous metastasis of Crohn's disease].
Masmoudi A; Abdelmaksoud W; Bouassida S; Khabir A; Charfeddine A; Fourati H; Boudawara T; Baklouti S; Krichen M; Turki H; Zahaf A
Presse Med; 2006 Feb; 35(2 Pt 1):230-2. PubMed ID: 16493351
[TBL] [Abstract][Full Text] [Related]
15. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group.
Mortimore M; Gibson PR; Selby WS; Radford-Smith GL; Florin TH;
Intern Med J; 2001 Apr; 31(3):146-50. PubMed ID: 11478343
[TBL] [Abstract][Full Text] [Related]
16. Metastatic vulval Crohn's disease and infliximab: a case report.
Tritton SM; Whyte L; Fischer G
J Reprod Med; 2009 Jan; 54(1):41-4. PubMed ID: 19263879
[TBL] [Abstract][Full Text] [Related]
17. [Successful primary infliximab treatment of orofacial Crohn's disease without gastrointestinal manifestation].
Jung BY; Lee SH; Chung SK; Lee CK; Lee TH; Chung IK; Kim SJ; Cho HD
Korean J Gastroenterol; 2012 Jun; 59(6):437-40. PubMed ID: 22735878
[TBL] [Abstract][Full Text] [Related]
18. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Crohn's disease: an underestimated entity.
Ickrath F; Stoevesandt J; Schulmeyer L; Glatzel C; Goebeler M; Kerstan A
J Dtsch Dermatol Ges; 2021 Jul; 19(7):973-982. PubMed ID: 33960613
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Crohn's disease treated with infliximab and 4 years of follow up.
Yoong C; Schofield C; Rodins K; Faulkner C
Australas J Dermatol; 2014 Aug; 55(3):e40-3. PubMed ID: 23772972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
